Alkermes (ALKS) Downgraded to Underperform

Alkermes, Inc. (ALKS) reported a fourth quarter fiscal 2010 net loss of $0.12 per share compared with a loss of $0.13 in the year-ago period. Revenues in the quarter slipped 12.3% due to lower manufacturing revenues for Risperdal Consta.

We believe that even if Alkermes diabetes candidate Bydureon is approved by the US FDA later in the year (target date: October 22, 2010), the final label will contain warnings regarding the risk of pancreatitis and thyroid cancer. Furthermore, the candidate will face intense competition once it enters the market.

In view of these factors, we downgrade the stock to Underperform from Neutral with a price target of $11.00.

ALKERMES INC (ALKS): Free Stock Analysis Report
Zacks Investment Research

About Zacks Investment Research 1767 Articles

Zacks Investment Research is one of the most highly regarded firms in the investment industry. In 1978 Zacks originated the concept of utilizing earnings estimates revisions to make profitable investment decisions. Zacks offers multiple investment products and services to help investors achieve superior returns.


Be the first to comment

Leave a Reply

Your email address will not be published.